Phaseline

Targets › LPA

LPA (Apolipoprotein(a)): drug programs, companies and trials

4 programs from 4 companies in 11 trials: 9 Phase 3, 1 Phase 2, 1 Phase 1; Cardiovascular; next expected readout Jul 2027.

Apo(a) is the main constituent of lipoprotein(a) (Lp(a)). It has serine proteinase activity and is able of autoproteolysis. (UniProt, P08519)

Open in Phaseline: the race on LPA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NovartisPelacarsen (TQJ230)
LPA mRNA antisense inhibitor
LPAPhase 3Atherosclerotic Cardiovascular Disease (ASCVD); Hyperlipoproteinemia (a); Cardiovascular Disease and Lipoprotein(a); Atherosclerotic Cardiovascular Disease …Feb 2028
AmgenOlpasiran
LPA mRNA rnai inhibitor
LPAPhase 3Atherosclerotic Cardiovascular Disease; Cardiovascular DiseaseMar 2028
Eli LillyLepodisiran Sodium
Lipoprotein(a) synthesis inhibitor (antisense oligonucleotide)
LPAPhase 3Atherosclerotic Cardiovascular Disease (ASCVD); AtherosclerosisMar 2029
Bisirna Therapeutics (Suzhou)BSA204
LPA antisense oligonucleotide inhibitor
LPAPhase 1DyslipidemiasJul 2027

Conditions

Atherosclerotic Cardiovascular Disease (2) Cardiovascular Disease (2) Atherosclerotic Cardiovascular Disease (ASCVD) (2) Hyperlipoproteinemia (a) (1) Cardiovascular Disease and Lipoprotein(a) (1) Aortic Stenosis (1) Dyslipidemias (1) Atherosclerosis (1)

Modalities

other (3), small molecule (1)

Companies

Amgen (1) Novartis (1) Bisirna Therapeutics (Suzhou) (1) Eli Lilly (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.